Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
Transforming growth factor (TGF)-beta2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-beta2 in an open-label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-beta2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.
Calabresi
P A
PA
Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA.
Fields
N S
NS
Maloni
H W
HW
Hanham
A
A
Carlino
J
J
Moore
J
J
Levin
M C
MC
Dhib-Jalbut
S
S
Tranquill
L R
LR
Austin
H
H
McFarland
H F
HF
Racke
M K
MK
D000328:Adult; D001806:Blood Urea Nitrogen; D002555:Cerebrospinal Fluid / Q000166:cytology; D002908:Chronic Disease; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012079:Renal Circulation / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity*
D016212:Transforming Growth Factor beta